# Anterogen Co., Ltd. clinical trials: 31 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 31 trials with Anterogen Co., Ltd. as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Anterogen Co., Ltd.: 31 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/anterogen-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 31
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 31, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 6, 2024 | NCT06539429 | Clinical Study to Evaluate Efficacy and Safety of ANT-301 in Patients With Knee Osteoarthritis in Grade III/IV by K/L | Anterogen Co., Ltd. | Phase 1 | Active not recruiting | Osteoarthritis, Knee | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06539429) |
| November 21, 2023 | NCT06141811 | A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-302 Clinical Trial | Anterogen Co., Ltd. | Observational | Recruiting | Diabetic Foot Ulcer | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06141811) |
| December 15, 2021 | NCT05157958 | Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa | Anterogen Co., Ltd. | Phase 2 | Unknown | Dystrophic Epidermolysis Bullosa | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05157958) |
| November 3, 2020 | NCT04612465 | Clinical Study to Evaluate Efficacy and Safety of ASC and Fibringlue or Fibringlue in Patients With Crohn's Fistula | Anterogen Co., Ltd. | Phase 3 | Active not recruiting | Crohn's Fistula | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04612465) |
| October 19, 2020 | NCT04590703 | A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-301 Clinical Trial | Anterogen Co., Ltd. | Observational | Completed | Diabetic Foot Ulcer | 73 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04590703) |
| September 29, 2020 | NCT04569409 | Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Wagner Grade 2 Foot Ulcers. | Anterogen Co., Ltd. | Phase 3 | Completed | Diabetic Foot Ulcer | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04569409) |
| August 4, 2020 | NCT04497805 | Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers | Anterogen Co., Ltd. | Phase 2 | Unknown | Diabetic Foot Ulcer | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04497805) |
| November 27, 2018 | NCT03754465 | Clinical Study of ALLO-ASC-SHEET in Subjects with Diabetic Foot Ulcers | Anterogen Co., Ltd. | Phase 2 | Completed | Diabetic Foot Ulcer | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03754465) |
| December 13, 2017 | NCT03370874 | Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers. | Anterogen Co., Ltd. | Phase 3 | Completed | Diabetic Foot Ulcer | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03370874) |
| June 12, 2017 | NCT03183934 | A Follow-up Study to Evaluate the Efficacy and Safety of ALLO-ASC-DFU in ALLO-ASC-EB-101 Clinical Trial | Anterogen Co., Ltd. | Observational | Completed | Dystrophic Epidermolysis Bullosa | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03183934) |
| June 12, 2017 | NCT03183804 | A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-201 Clinical Trial | Anterogen Co., Ltd. | Observational | Completed | Diabetic Foot Ulcer | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03183804) |
| June 12, 2017 | NCT03183726 | A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-101 Clinical Trial | Anterogen Co., Ltd. | Observational | Completed | Diabetic Foot Ulcer | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03183726) |
| June 12, 2017 | NCT03183661 | A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial | Anterogen Co., Ltd. | Observational | Recruiting | Crohn Disease | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03183661) |
| June 12, 2017 | NCT03183648 | A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-BI-201 Clinical Trial | Anterogen Co., Ltd. | Observational | Completed | Burn | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03183648) |
| June 12, 2017 | NCT03183622 | A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-BI-101 Clinical Trial | Anterogen Co., Ltd. | Observational | Completed | Burn | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03183622) |
| December 2, 2015 | NCT02619877 | Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers | Anterogen Co., Ltd. | Phase 2 | Completed | Diabetic Foot Ulcer | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02619877) |
| December 2, 2015 | NCT02619851 | A Clinical Trial to Evaluate the Safety and Efficacy of ALLO-ASC-DFU for Second Deep Degree Burn Injury Subjects | Anterogen Co., Ltd. | Phase 2 | Completed | Burn Injury | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02619851) |
| October 20, 2015 | NCT02580617 | A Study to Evaluate the Safety of ALLO-ASC-CD for Treatment of Crohn's Disease | Anterogen Co., Ltd. | Phase 1 | Unknown | Crohn's Disease | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02580617) |
| October 19, 2015 | NCT02579369 | Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa | Anterogen Co., Ltd. | Phase 1/2 | Completed | Dystrophic Epidermolysis Bullosa | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02579369) |
| March 20, 2015 | NCT02394886 | Safety of ALLO-ASC-DFU in the Patients With Diabetic Foot Ulcers | Anterogen Co., Ltd. | Phase 1 | Completed | Diabetic Foot Ulcer | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02394886) |
| March 20, 2015 | NCT02394873 | A Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Deep Second-degree Burn Wound | Anterogen Co., Ltd. | Phase 1 | Completed | Burn | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02394873) |
| May 6, 2014 | NCT02131077 | Safety and Efficacy Study of Allogeneic Adipose-derived Stem Cells for Treatment of Lateral Epicondylitis | Anterogen Co., Ltd. | Phase 1/2 | Completed | Tennis Elbow | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02131077) |
| December 3, 2012 | NCT01739530 | Safety of Repaircell in Healthy Volunteers | Anterogen Co., Ltd. | Phase 1 | Completed | Healthy | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01739530) |
| June 20, 2012 | NCT01623453 | Follow-up Study of Autologous Adipose-derived Stem Cells (ANTG-ASC) for the Complex Fistula (ANTG-ASC-211) | Anterogen Co., Ltd. | Observational | Terminated | Perianal Fistula, Primary; Complex | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01623453) |
| September 26, 2011 | NCT01440699 | Study of Allogenic Adipose-derived Stem Cells in Crohn's Fistula | Anterogen Co., Ltd. | Phase 1 | Completed | Crohn | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01440699) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 8 |
| Phase 1/2 | 2 |
| Phase 2 | 7 |
| Phase 2/3 | 1 |
| Phase 3 | 3 |
| Observational | 10 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 21 |
| Terminated | 3 |
| Unknown | 3 |
| Active not recruiting | 2 |
| Recruiting | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Diabetic Foot | 10 |
| Crohn Disease | 5 |
| Burns | 4 |
| Fistula | 3 |
| Epidermolysis Bullosa Dystrophica | 3 |
| Epidermolysis Bullosa | 2 |
| Osteoarthritis, Knee | 1 |
| Tennis Elbow | 1 |
| Fecal Incontinence | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Mortgage lenders in the United States](https://specstream.ai/data/businesses/mortgage-lenders/united-states)
- [Shoe factory manufacturers in the United States](https://specstream.ai/data/businesses/shoe-factory-manufacturers/united-states)
- [Apparel manufacturers in the United States](https://specstream.ai/data/businesses/apparel-manufacturers/united-states)
- [Computer training centers in the United States](https://specstream.ai/data/businesses/computer-training-centers/united-states)
- [Guest houses in the United States](https://specstream.ai/data/businesses/guest-houses/united-states)
- [Nicaraguan restaurants in the United States](https://specstream.ai/data/businesses/nicaraguan-restaurants/united-states)
